In the HYVET trial, antihypertensive treatment with sustained-release indapamide, with or without perindopril, reduced death from any cause by 21% (95% CI, 4 to 35; P=0.02) among patients aged 80 years or older.
Notes on verification
Directly matches the primary published HYVET trial results (Beckett et al., NEJM 2008), consistently cited in subsequent guidelines and reviews without contradiction. [tier=silver indep_score=1.0 clusters=2 claim_tier=notable | framework convergence=single on HYVET trial original publication and its PubMed-indexed abstract (upstreams: HYVET (Hypertension in the Very Elderly Trial) - Beckett et al., NEJM 2008) — publishers independent, evidence may not be | kind=empirical eligibility=high]
Sources
- Treatment of Hypertension in Patients 80 Years of Age or Older | NEJM (seed:health_and_medicine)
- https://pubmed.ncbi.nlm.nih.gov/18378519/ (corroboration)
- https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.108.113357 (corroboration)